Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/55660
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDalai, Chanchal Kumar-
dc.contributor.authorSarkar, Deblina-
dc.contributor.authorGhosh, Abhishek-
dc.contributor.authorAhmed, Shah Newaz-
dc.contributor.authorDas, Subir Kumar-
dc.contributor.authorRoy, Suman Kumar-
dc.contributor.authorMukhopadhyay, Keshab-
dc.date.accessioned2020-11-23T06:51:47Z-
dc.date.available2020-11-23T06:51:47Z-
dc.date.issued2020-12-
dc.identifier.issn0975-0959 (Online); 0301-1208 (Print)-
dc.identifier.urihttp://nopr.niscair.res.in/handle/123456789/55660-
dc.description707-712en_US
dc.description.abstractHydroxychloroquine, an antimalarial, is being used worldwide for prophylaxis and treatment of Corona virus disease-19 (COVID-19). Though the drug is commonly used in many chronic inflammatory diseases for protracted periods, its safety in the new indication is still under scrutiny. Therefore, this institute based study sought to assess the acute adverse effects of hydroxychloroquine among in-house health care professionals who were taking the drug for COVID-19 prophylaxis. A questionnaire seeking information on the use of the drug was prepared and disseminated electronically to the target population. The responses were also received electronically and analysed. The participants (n=54) had taken prophylaxis for 1-7 weeks. The most common adverse effects in the cohort were nausea (02) and skin rash (02). The total number of adverse effects reported by the participants was 08. One incidence each of gastric upset (01), dizziness (01), pain abdomen (01), and chest tightness (01) was reported. None of the adverse effects were serious. Our study indicates that the prophylactic weekly single dose of hydroxychloroquine is not associated with any serious adverse effects within 1-7 weeks of initiation. Elucidation of the long term and chronic adverse effects, if any, requires further studies.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJBB Vol.57(6) [December 2020]en_US
dc.subjectHydroxychloroquineen_US
dc.subjectOndansetronen_US
dc.subjectProphylaxisen_US
dc.subjectSystemic lupus erythematousen_US
dc.titleAcute effects of hydroxychloroquine prophylaxis for COVID-19 in health care professionals – An online surveyen_US
dc.typeArticleen_US
Appears in Collections:IJBB Vol.57(6) [December 2020]

Files in This Item:
File Description SizeFormat 
IJBB 57(6) 707-712.pdf489.4 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.